Mast Cells are Important Modifiers of Autoimmune Disease: With so Much Evidence, Why is There Still Controversy?
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
There is abundant evidence that mast cells are active participants in events that mediate tissue damage in autoimmune disease. Disease-associated increases in mast cell numbers accompanied by mast cell degranulation and elaboration of numerous mast cell mediators at sites of inflammation are commonly observed in many human autoimmune diseases including multiple sclerosis, rheumatoid arthritis, and bullous pemphigoid. In animal models, treatment with mast cell stabilizing drugs or mast cell ablation can result in diminished disease. A variety of receptors including those engaged by antibody, complement, pathogens, and intrinsic danger signals are implicated in mast cell activation in disease. Similar to their role as first responders in infection settings, mast cells likely orchestrate early recruitment of immune cells, including neutrophils, to the sites of autoimmune destruction. This co-localization promotes cellular crosstalk and activation and results in the amplification of the local inflammatory response thereby promoting and sustaining tissue damage. Despite the evidence, there is still a debate regarding the relative role of mast cells in these processes. However, by definition, mast cells can only act as accessory cells to the self-reactive T and/or antibody driven autoimmune responses. Thus, when evaluating mast cell involvement using existing and somewhat imperfect animal models of disease, their importance is sometimes obscured. However, these potent immune cells are undoubtedly major contributors to autoimmunity and should be considered as important targets for therapeutic disease intervention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toll-like receptors and their crosstalk with other innate receptors in infection and immunity
Kawai, T., & Akira, S. (2011) · Immunity · doi:10.1016/j.immuni.2011.05.006 · Cited by 3,658 · cited 1×
“…or in endosomal compartments and recognize conserved components of bacteria, viruses, and protozoa (such as lipopolysaccharide, LPS), double stranded RNA, flagellin, and non-methylated CpG DNA, collectively termed pathogen associated molecular patterns (PAMPs; reviewed in Kawai and Akira, 2011).”
BackgroundComplement: a key system for immune surveillance and homeostasis
Ricklin, D., Hajishengallis, G., Yang, K., & Lambris, J. D. (2010) · Nature Immunology · doi:10.1038/ni.1923 · Cited by 3,654 · cited 1×
“Under inflammatory conditions, a proteolytic cascade is initiated that results in the cleavage and generation of active components, some of which act as direct chemoattractants or bind to specific G protein-coupled receptors on cells and stimulate their activation (reviewed in Ricklin et al., 2010).”
BackgroundDAMPs, PAMPs and alarmins: all we need to know about danger
Bianchi, M. E. (2007) · Journal of Leukocyte Biology · doi:10.1189/jlb.0306164 · Cited by 2,794 · cited 1×
“TLRs and NLRs (reviewed in Bianchi, 2007; Piccinini and Midwood, 2010; Marek and Kagan, 2012).”
Immunology of multiple sclerosis
Sospedra, M., & Martin, R. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115707 · Cited by 2,149
Genetics, pathogenesis and clinical interventions in type 1 diabetes
Bluestone, J. A., Herold, K., & Eisenbarth, G. (2010) · Nature · doi:10.1038/nature08933 · Cited by 1,265 · cited 1×
“The resulting loss of blood glucose regulation can lead to retinopathy, neuropathy, cardiovascular disease, and nephropathy (Bluestone et al., 2010).”
BackgroundMast cells are essential intermediaries in regulatory T-cell tolerance
Lu, L.-F., Lind, E. F., Gondek, D. C., Bennett, K. A., Gleeson, M. W., Pino-Lagos, K., Scott, Z. A., Coyle, A. J., Reed, J. L., Van Snick, J., et al. (2006) · Nature · doi:10.1038/nature05010 · Cited by 751 · cited 2×
“…molecules such as CD80, CD86, CD40, CD40L, GITR, and 4-1BB as well as the inhibitory molecules PD-L1, PD-L2, and Fas, mast cells can alter T cell effector function (Nakae et al., 2005, 2007c; Lu et al., 2006; Stelekati et al., 2007, 2009; Piconese et al., 2009; Hershko and Rivera, 2010).”
BackgroundAbdollahi-Roodsaz, S., Joosten, L. A. B., Koenders, M. I., Devesa, I., Roelofs, M. F., Radstake, T. R. D. J., Heuvelmans-Jacobs, M., Akira, S., Nicklin, M. J. H., Ribeiro-Dias, F., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci32639 · Cited by 527 · cited 1×
“Activation through TLR2, 3, 4, and 9 is associated with disease in animal models of RA (Ronaghy et al., 2002; Abdollahi-Roodsaz et al., 2008; Hoffmann et al., 2011; Goh and Midwood, 2012) and TLR4 engagement can overcome the requirement for IL-1β in the serum transfer model of this disease (Choe et…”
BackgroundPathophysiology of allergic inflammation
Barnes, P. J. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01020.x · Cited by 361 · cited 1×
“Given the emerging appreciation of superantigens in allergic pathogenesis, particularly those derived from Staphylococcus (Barnes, 2011), it is tempting to speculate that mast cells “present” superantigens to T cells and initiate their activation.”
BackgroundIL-33 induces neutrophil migration in rheumatoid arthritis and is a target of anti-TNF therapy
Verri, W. A., Souto, F. O., Vieira, S. M., Almeida, S. C. L., Fukada, S. Y., Xu, D., Alves-Filho, J. C., Cunha, T. M., Guerrero, A. T. G., Mattos-Guimaraes, R. B., et al. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.122655 · Cited by 263
Baram, D., Vaday, G. G., Salamon, P., Drucker, I., Hershkoviz, R., & Mekori, Y. A. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.7.4008 · Cited by 233
Cited by
Mast Cell Function: A New Vision of an Old Cell
da Silva, E. Z. M., Jamur, M. C., & Oliver, C. (2014) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155414545334 · Cited by 604
Mast Cell Biology at Molecular Level: a Comprehensive Review
Elieh Ali Komi, D., Wöhrl, S., & Bielory, L. (2020) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-019-08769-2 · Cited by 371
Kempuraj, D., Thangavel, R., Selvakumar, G. P., Zaheer, S., Ahmed, M. E., Raikwar, S. P., Zahoor, H., Saeed, D., Natteru, P. A., Iyer, S., et al. (2017) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2017.00216 · Cited by 365
Hair follicle immune privilege and its collapse in alopecia areata
Bertolini, M., McElwee, K., Gilhar, A., Bulfone‐Paus, S., & Paus, R. (2020) · Experimental Dermatology · doi:10.1111/exd.14155 · Cited by 318
Mast cells on the mind: new insights and opportunities
Silver, R., & Curley, J. P. (2013) · Trends in Neurosciences · doi:10.1016/j.tins.2013.06.001 · Cited by 176
“Therefore, it has been argued that MCs regulate both the induction and effector phases of EAE via their involvement in the autoimmune response in peripheral lymphoid organs and their gatekeeping role at the BBB [18].”
InfluentialNew models for analyzing mast cell functions in vivo
Reber, L. L., Marichal, T., & Galli, S. J. (2012) · Trends in Immunology · doi:10.1016/j.it.2012.09.008 · Cited by 171
Approaches for Analyzing the Roles of Mast Cells and Their Proteases In Vivo
Galli, S. J., Tsai, M., Marichal, T., Tchougounova, E., Reber, L. L., & Pejler, G. (2015) · Advances in Immunology · doi:10.1016/bs.ai.2014.11.002 · Cited by 101
Evidence that Meningeal mast cells can worsen stroke pathology in mice.
Arac, A., Grimbaldeston, M. A., Nepomuceno, A. R. B., Olayiwola, O., Pereira, M. P., Nishiyama, Y., Tsykin, A., Goodall, G. J., Schlecht, U., Vogel, H., et al. (2014) · The American Journal of Pathology · doi:10.1016/j.ajpath.2014.06.003 · Cited by 74
“05 level of statistical significance, perhaps because of phenotypic differences between C57BL/6 WT and Kit sh/W sh mice other than the MC deficiency of the Kit sh/W sh mice.(30,34,35) Moreover, we provide strong evidence that meningeal MCs were sufficient to elicit the detrimental effects of MCs after stroke.”
BackgroundMast cells and IgE in defense against venoms: Possible “good side” of allergy?
Galli, S. J., Starkl, P., Marichal, T., & Tsai, M. (2016) · Allergology International · doi:10.1016/j.alit.2015.09.002 · Cited by 73
Mast cells and IgE in defense against lethality of venoms: Possible “benefit” of allergy
Galli, S. J., Metz, M., Starkl, P., Marichal, T., & Tsai, M. (2020) · Allergo Journal International · doi:10.1007/s40629-020-00118-6 · Cited by 57
Sprinzl, B., Greiner, G., Uyanik, G., Arock, M., Haferlach, T., Sperr, W. R., Valent, P., & Hoermann, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052458 · Cited by 51
Akyol, G. Y., Manaenko, A., Akyol, O., Solaroglu, I., Ho, W. M., Ding, Y., Flores, J., Zhang, J. H., & Tang, J. (2017) · Scientific Reports · doi:10.1038/s41598-017-15455-w · Cited by 25
Metadata
- Authors
- Brown, M. A., & Hatfield, J. K.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2012
- Volume
- 3
- Pages
- 147-147
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2058343152
- Cited by
- 108
- References
- 11
- FWCI
- 5.18
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.